FDA Warns Tides Medical Over APLICOR 3D Distribution
The agency says the device lacks required marketing clearance for treating wounds like diabetic foot ulcers and burns.
Updated on Oct. 20, 2026 in Healthcare
Live Poll
Should companies be allowed to distribute new medical devices before receiving federal marketing clearance?
The FDA has issued a warning to Tides Medical LLC for the unauthorized distribution of its APLICOR 3D device. Regulators state the product is being marketed for wound treatment without necessary federal clearance or approval.
Why it matters
The FDA flagged the product because its intended use in treating conditions like burns and diabetic foot ulcers exceeds its classification as a simple liquid medication dispenser. Without proper oversight, such devices pose potential safety risks to patients in the United States.
The firm faces a deadline of 15 business days to provide a formal written response to the FDA regarding corrective actions. This mandate follows the agency's determination that the device exceeds existing Class I liquid dispenser exemptions.
The players
FDA
The Food and Drug Administration is a federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices.
Tides Medical LLC
Tides Medical LLC is a medical device firm that specializes in developing bioprinting platforms for the creation of patient-specific grafts.
The details
Tides Medical LLC markets the platform as a 3D bioprinting tool that utilizes a patient's own adipose tissue to create customized grafts. The FDA identified the device as requiring premarket approval or an investigational exemption, neither of which the company currently possesses.
Timeline
February 25, 2026: FDA Center for Devices and Radiological Health sent a letter to the firm.
February 26, 2026: Tides Medical LLC sent initial correspondence to the agency.
October 6, 2026: The FDA issued the formal warning letter to the company.
15 business days from receipt: The firm must submit a written response detailing how it will address the violations.
Market Landscape
This enforcement action aligns with the FDA's broader oversight of the rapidly evolving field of personalized medical grafts and 3D bioprinting platforms. By enforcing classification standards under section 201(h) of the Federal Food, Drug, and Cosmetic Act, the agency aims to ensure that high-risk medical innovations undergo rigorous premarket review before reaching patients.
Patients and healthcare providers currently utilizing APLICOR 3D should be aware that the device is under regulatory scrutiny due to a lack of federal clearance. The FDA's warning may disrupt the availability of this specific treatment platform as the company works to address its compliance requirements.
The takeaway
The FDA warning serves as a reminder that companies must secure formal clearance before marketing medical devices for high-risk applications like wound treatment. Providers should verify the regulatory status of all medical technology used in patient care to ensure compliance and safety standards.
What happens next
Tides Medical LLC must submit a written response to the FDA within 15 business days of receipt of the October 6, 2026, letter. Failure to resolve these violations could lead to further regulatory actions, including potential seizure, injunction, or civil money penalties.
Further reading
Learn more about federal oversight of new medical technologies in our Healthcare section.
More information
For official guidelines on bringing medical products to market, consult the FDA device regulation and guidance information.
Source note: This article includes information reported by U.S. Food and Drug Administration.
Live Poll
Should companies be allowed to distribute new medical devices before receiving federal marketing clearance?
